NFKB1 and breast carcinoma: As a first assay, breast cancer MDA‐MB‐231 cells were treated with TWEAK, which is known to stimulate Fn14 signaling through the NFκB pathway, resulting in phosphorylation and subsequent degradation of the NFκB inhibitor IκB (Burkly, 2014).